Rangeley Capital, LLC Macrogenics Inc Transaction History
Rangeley Capital, LLC
- $116 Billion
- Q3 2025
A detailed history of Rangeley Capital, LLC transactions in Macrogenics Inc stock. As of the latest transaction made, Rangeley Capital, LLC holds 30,220 shares of MGNX stock, worth $46,538. This represents 0.04% of its overall portfolio holdings.
Number of Shares
30,220
Previous 27,000
11.93%
Holding current value
$46,538
Previous $32.7 Million
55.4%
% of portfolio
0.04%
Previous 0.04%
Shares
2 transactions
Others Institutions Holding MGNX
# of Institutions
111Shares Held
50MCall Options Held
65.5KPut Options Held
93.9K-
Bellevue Group Ag Kuesnacht, V89.92MShares$15.3 Million0.36% of portfolio
-
Armistice Capital, LLC New York, NY5.96MShares$9.18 Million0.16% of portfolio
-
Black Rock Inc. New York, NY5.4MShares$8.32 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.22MShares$6.51 Million0.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.18MShares$4.89 Million0.23% of portfolio
About MACROGENICS INC
- Ticker MGNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,458,800
- Market Cap $94.6M
- Description
- MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...